About Quantum Genomics

Company Description

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on Brain Aminopeptidase A inhibition (BAPAI) , which results from more than twenty years of academic research in the laboratories of the Collège de France, INSERM and CNRS.

The research conducted by the team of Professor Bernard-Pierre Roques (INSERM U1022 / CNRS Unit/ Université Paris Descartes) and the team of Dr. Catherine Llorens-Cortes (INSERM U1050 / Collège de France) characterized the role of the brain renin-angiotensin system (RAS) and more particularly that of aminopeptidase A (APA) in the control of certain cardiovascular functions including blood pressure.

Year founded

2005

Served area

Worldwide

Headcount

7

Headquarters

33 Rue Marbeuf, 75008 Paris – France

Shareholder information

Shares outstanding

34,619,981

IPO

April 10, 2014

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.